| Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models A McCampbell, T Cole, AJ Wegener, GS Tomassy, A Setnicka, BJ Farley, ... The Journal of clinical investigation 128 (8), 3558-3567, 2018 | 222 | 2018 |
| P68 RNA helicase unwinds the human let-7 microRNA precursor duplex and is required for let-7-directed silencing of gene expression DW Salzman, J Shubert-Coleman, H Furneaux Journal of biological chemistry 282 (45), 32773-32779, 2007 | 137 | 2007 |
| SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer DW Salzman, JB Weidhaas Pharmacology & therapeutics 137 (1), 55-63, 2013 | 119 | 2013 |
| miR-34 activity is modulated through 5′-end phosphorylation in response to DNA damage DW Salzman, K Nakamura, S Nallur, MT Dookwah, C Metheetrairut, ... Nature communications 7 (1), 10954, 2016 | 77 | 2016 |
| A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy Z Saridaki, JB Weidhaas, HJ Lenz, P Laurent-Puig, B Jacobs, ... Clinical Cancer Research 20 (17), 4499-4510, 2014 | 74 | 2014 |
| The 5′ terminal uracil of let-7a is critical for the recruitment of mRNA to Argonaute2 KM Felice, DW Salzman, J Shubert-Coleman, KP Jensen, HM Furneaux Biochemical Journal 422 (2), 329-341, 2009 | 31 | 2009 |
| Estrogen withdrawal, increased breast cancer risk and the KRAS-variant TP McVeigh, SY Jung, MJ Kerin, DW Salzman, S Nallur, AA Nemec, ... Cell Cycle 14 (13), 2091-2099, 2015 | 17 | 2015 |
| A germline mutation in the BRCA13’UTR predicts Stage IV breast cancer JJ Dorairaj, DW Salzman, D Wall, T Rounds, C Preskill, CAW Sullivan, ... BMC cancer 14, 1-11, 2014 | 17 | 2014 |
| miRNAs in the spotlight: Making'silent'mutations speak up DW Salzman, JB Weidhaas Nature medicine 17 (8), 934-935, 2011 | 11 | 2011 |
| The KRAS-variant and its impact on normal breast epithelial cell biology S Jung, P Malhotra, KC Nguyen, D Salzman, Y Qi, EH Pak, J King, ... Cell Death & Differentiation 26 (12), 2568-2576, 2019 | 5 | 2019 |
| Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. JB Weidhaas, D Telesca, A Kalbasi, D Salzman, A Ribas Journal of Clinical Oncology 35 (15_suppl), 3040-3040, 2017 | 5 | 2017 |
| The Non-Coding RNA Journal Club: Highlights on Recent Papers—4 D Gautheret, JH Taube, SA Mani, G Santulli, D Cuerda-Gil, RK Slotkin, ... Non-coding RNA 2 (3), 9, 2016 | 1 | 2016 |
| Small rna disease classifiers DW Salzman, AP Salzman, NC Foster, T Melconian US Patent App. 17/794,047, 2023 | | 2023 |
| Analyzing Nuclear Paraspeckle-Dependent Protection of Unphosphorylated microRNAs GH Read University of California, Los Angeles, 2023 | | 2023 |
| Small rna predictors for alzheimer's disease DW Salzman, AP Salzman, NC Foster US Patent App. 17/262,045, 2021 | | 2021 |
| Methods for identifying and using small rna predictors D Salzman US Patent App. 17/313,191, 2021 | | 2021 |
| Methods for identifying and using small RNA predictors D Salzman US Patent 11,028,440, 2021 | | 2021 |
| Methods for identifying and using small RNA predictors D Salzman US Patent 10,889,862, 2021 | | 2021 |
| Small rna predictors for huntington's disease D Salzman US Patent App. 16/630,127, 2020 | | 2020 |
| A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. JB Weidhaas, AW Scheffler, D Salzman, A Kalbasi, K Wilenius, E Rietdorf, ... Journal of Clinical Oncology 37 (8_suppl), 96-96, 2019 | | 2019 |
